Simon Jones Announced as GrayMatterAI CEO in Growing Specialty Drug Healthcare Analytics

ORANGE COUNTY, Calif., Oct. 17, 2018 /PRNewswire-PRWeb/ -- GrayMatterAI, whose analytics platform leverages machine learning techniques to identify the most clinically effective specialty medications at an optimal cost, appoints Simon Jones as Chief Executive Officer. He joins at a strategically crucial time for GrayMatterAI which has recently added 2 seasoned industry leaders to the board of directors, namely, Teri Mullaney and Cathy Eddy. GrayMatterAI sees accelerated growth opportunities based on their early successes with key customers as the industry moves to more highly prioritize precision medicine, evidence-based clinical decision support and application of risk strategies maximizing revenue and streamlining care pathways across healthcare systems.

"As a member of the board and someone who has worked with Simon in the past, we are excited to have such a seasoned and strategic leader on our team ready to take on this critical role," said Teri Mullaney, board member at GrayMatterAI. "With Simon's 25 years of healthcare leadership experience, GrayMatterAI is poised to ride this very large market wave in front of us."

"GrayMatterAI's machine learning solutions are an ideal fit for provider-sponsored health plans challenged with managing risk with high cost specialty drugs," said Health Plan Alliance founder and GrayMatterAI board member Cathy Eddy. "Simon's significant experience in operationalizing real-world data will provide plans a distinct advantage in improving outcomes and containing costs."

Simon Jones is a seasoned leader and visionary in the advanced analytics and healthcare industry with an exceptional track record for driving innovation and delivering customer-specific solutions. Prior to GrayMatterAI, Simon was Chief Product Officer for Optima Curis, Inc. a patient engagement platform provider. He also held leadership roles in healthcare technology for CandleStick Health, Blue Shield of California, and Humana.

"As a seasoned healthcare technology executive I have long believed that the ability to apply insights at the individual patient level using large data sets is key to managing clinical outcomes and cost. GrayMatterAI's proprietary machine learning solutions close the loop in efficiently extracting valuable insights from disparate data which is why I decided to join this novel company," Jones said. "GrayMatterAI will give organizations adopting our unique capabilities an optimal combination of economic and clinical value for their patients", Jones says.

About GrayMatterAI

GrayMatterAI exists to improve health outcomes and eliminate waste by optimizing each patient's unique specialty drug prescription decision. We incorporate machine learning and predictive analytics to ensure that patients are getting the most effective treatment for their specific case. This ensures each patient is prescribed a treatment precisely tailored to them, eliminates inappropriate specialty drug use, and lowers the overall cost burden on the healthcare system.

GrayMatterAI is privately funded and based in Orange County, CA. For more information, visit http://www.graymatterai.com or email info(at)graymatterai.com.

SOURCE GrayMatterAI